Keryx Biopharmaceuticals (KERX) 1.65 -0.06

Keryx Biopharmaceuticals, Inc.
(KERX) 1.65 -0.06

Last Trade:	1.64	Day Range:	1.64 - 1.71
Trade Time:	08:05PM	52wk Range:	1.28 - 5.19
Prev. Close:	1.70	Market Cap:	116.76M
Open:	1.65	Div Yield:	0
Volume:	1175672	PE:
EPS:	-0.45

The Latest On KERX

Benzinga's Top Upgrades with Color for May 10, 2012 5/10/12 12:02pm

UPDATE: Ladenburg Thalmann Upgrades Keryx Biopharmaceuticals; Establishes PT 5/10/12 10:54am

Aeterna Zentaris Regains North American Rights for Perifosine from Keryx 5/7/12 7:36am

Aeterna Zentaris Regains North American Rights for Perifosine from Keryx 5/7/12 7:31am

Keryx Biopharmaceuticals Announces Positive Top-Line Results from Phase 3 Study of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical 4/23/12 8:38am

UPDATE: Stifel Nicolaus Reduces Target to $4 on Keryx Biopharmaceuticals 4/3/12 10:52am

Keryx Biopharmaceuticals Down 65% on Negative Clinical Trial Results 4/2/12 10:29am

Morning Social Media Outlook for Monday April 2 (AVP, ESRX, D, GEO) 4/2/12 10:25am

Morning Market Losers 4/2/12 10:07am

Financial Breakfast: Morning News Summary for April 2, 2012 4/2/12 7:38am

Aeterna Zentaris Announces Top-Line Data from the Perifosine Phase 3 Trial in Refractory Advanced Colorectal Cancer; Did not Meet Primary Endpoint 4/2/12 7:05am

Benzinga's Top Upgrades with Color for May 10, 2012 5/10/12

UPDATE: Ladenburg Thalmann Upgrades Keryx Biopharmaceuticals; Establishes PT 5/10/12

Aeterna Zentaris Regains North American Rights for Perifosine from Keryx 5/7/12

Keryx Biopharmaceuticals Announces Positive Top-Line Results from Phase 3 Study of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical 4/23/12

UPDATE: Stifel Nicolaus Reduces Target to $4 on Keryx Biopharmaceuticals 4/3/12

Keryx Biopharmaceuticals Down 65% on Negative Clinical Trial Results 4/2/12

Morning Social Media Outlook for Monday April 2 (AVP, ESRX, D, GEO) 4/2/12

Morning Market Losers 4/2/12

Financial Breakfast: Morning News Summary for April 2, 2012 4/2/12

Aeterna Zentaris Announces Top-Line Data from the Perifosine Phase 3 Trial in Refractory Advanced Colorectal Cancer; Did not Meet Primary Endpoint 4/2/12

Morning Social Media Outlook for Monday April 2 (AVP, ESRX, D, GEO) 4/2/12

Financial Breakfast: Morning News Summary for April 2, 2012 4/2/12

Weekly Traders Homework: Positive Jobs Report Gives Bullish Sentiment (w/ Economic Calendar and Stock Radar) 3/12/12

Morning Social Media Outlook for Tuesday Mar 6 (SHFL, HAR, PCX, NTRI) 3/6/12

Calls Purchased on Keryx Biopharmaceuticals (KERX) 5/6/11

Puts Purchased on Keryx Biopharmaceuticals (KERX) 4/19/11

Pre-Market Top Percentage Gainers and Losers (XNPT, GSK, ZAGG, LOGI, BBBY, PRXL, BLUD, INHX, PWER, INTC, TZOO, KERX) 4/7/11

Mad Money Lightning Round OT: Cramer Is A Seller Of KERX (CELG, KERX, PRGO, JNJ, RBY, AEM) 11/30/10

Keryx Biopharma Pops; Attracts Call Buyers (KERX) 9/27/10

Keryx Reports In-Line Q2 Results 8/9/10

Puts Sold on Keryx Biopharma (KERX) 7/16/10

Calls Purchased on Keryx Biopharma (KERX) 7/14/10

Benzinga's Top Upgrades with Color for May 10, 2012 5/10/12

UPDATE: Ladenburg Thalmann Upgrades Keryx Biopharmaceuticals; Establishes PT 5/10/12

UPDATE: Stifel Nicolaus Reduces Target to $4 on Keryx Biopharmaceuticals 4/3/12

Morning Social Media Outlook for Monday April 2 (AVP, ESRX, D, GEO) 4/2/12

Financial Breakfast: Morning News Summary for April 2, 2012 4/2/12

Rodman & Renshaw Reiterates Keryx Market Outperform, $8 PT 11/15/11

Oppenheimer Maintains Outperform Rating and $8 PT on KERYX Biopharmaceuticals 11/15/11

McNicoll, Lewis & Vlak Maintains Keryx Biopharmaceuticals Buy, $18 PT 11/11/11

Rodman & Renshaw Outperform On Keryx Biopharmaceuticals 9/1/11

McNicoll, Lewis & Vlak Maintains Keryx Biopharmaceuticals Buy, $18 PT 8/31/11

Rodman & Renshaw Reiterates Market Outperform and PT of $8 on Keryx Biopharmaceuticals 7/28/11

Trade KERX
NOW!

Partner Headlines

Hey, They're Not Dead After All: KERX, BIEL, and AH Show Signs of Trade-Worthiness 5/15/12

BMC Software, The Ultimate Software Group Included in Stocks Up on High Volume Monday 5/14/12

8 Stocks Under $10 Soaring Higher 5/10/12

Can Keryx Succeed Without Partnership? 4/24/12

Galena's Breast Cancer Vaccine Doomed to Fail 4/24/12

Keryx Biopharmaceuticals Inc. (KERX) CEO Ron Bentsur buys 19,100 Shares 4/19/12

Keryx Still Has High Potential from Zerenex 4/12/12

Zacks' Voice of the People highlights opportunities with Starbucks, Realty Income, Keryx Biopharma, Bon-Ton Stores and Orexigen Therapeutics - Press Releases 4/12/12

Press Releases

KERX and GEAR are the Stocks to Watch for May 22nd from OTCPicks.com 5/22/12 Emailwire

Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress 5/21/12 Newswire

KERX and GEAR are the Daily Market Movers for May 21st from OTCPicks.com 5/21/12 Emailwire

DMED, KERX and DGRI are the Daily Market Movers for May 14th from OTCPicks.com 5/14/12 Emailwire

VIIC, KERX, ARNA and BBDA are the Stocks to Watch for May 14th from OTCPicks.com 5/14/12 Emailwire

CTIC, KERX, OBJE and WSGI are the Stocks to Watch for May 11th from OTCPicks.com 5/11/12 Emailwire

KERX, ARNA, BBDA and HRDN are the Daily Market Movers for May 11th from OTCPicks.com 5/11/12 Emailwire

Keryx Biopharmaceuticals to Present at The 11th Annual JMP Securities Research Conference 5/10/12 Newswire

KERX, OBJE, SNPK, WSGI and TKDN are the Daily Market Movers for May 10th from OTCPicks.com 5/10/12 Emailwire

Keryx Biopharmaceuticals Announces Upcoming Poster Presentations of Zerenex™ (ferric citrate) at National Kidney Foundation (NKF) 2012 Spring Clinical Meetings 5/9/12 Newswire

Get the latest KERX stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Keryx Biopharmaceuticals, Inc. stock price.

Keryx Biopharmaceuticals, Inc. by YCharts

Keryx Biopharmaceuticals (KERX) 1.65 -0.06

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On KERX

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social